MAP2K1 and melanoma: ✓an MEK1/2 inhibitor with an IC50 value of 0.92 and 1.8 nM, respectively [315]✓reduces p-RPS6 in naïve melanoma cells as a single agent treatment and dabrafenib resistant melanoma cells in combination with dabrafenib and trametinib (GSK1120212) [243]